retatrutide phase 2 study results just delivered the first top-line 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 VisualAbstract: Retatrutide reduces body weight

This effect has limited the use and production of GIP analogues as they may potentiate the diabetogenic glucagon effect through augmented gluconeogenesis and glycogenolysis

I am not receiving compensation for it (other than from Seeking Alpha)

Patients and clinicians should be aware that reflux-type symptoms are biologically plausible and have been reported in trial settings for this drug class, even if a definitive causal link has not been formally established for retatrutide specifically

Importantly, Retatrutide achieved its 24.2% result in 48 weeks while Tirzepatide required 72 weeks for its 20.9% result, suggesting Retatrutide produces faster weight loss

The primary concern is peptide denaturation, where elevated temperatures disrupt the hydrogen bonds and hydrophobic interactions that maintain the peptide's active three-dimensional structure